Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Liraglutide 6 MG/ML Pen InjectorDrug: MetforminDrug: Sulfonylurea/non-sulfonylurea insulin secretagogues
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2019-02-06
- Lead Sponsor
- Cinnagen
- Target Recruit Count
- 300
- Registration Number
- NCT03421119
Effect of Propolis or Metformin Administration on Glycemic Control in Patients With Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- University of Guadalajara
- Target Recruit Count
- 36
- Registration Number
- NCT03416127
- Locations
- 🇲🇽
Intstituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
Pilot Study of Metformin for Patients With Fanconi Anemia
- First Posted Date
- 2018-01-16
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT03398824
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
Metformin and Its Impact on the Substances Associated With NO Production in Prediabetes Patients.
- Conditions
- Impaired Glucose Tolerance (IGT)PreDiabetesImpaired Fasting Glucose (IFG)
- Interventions
- First Posted Date
- 2018-01-12
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- Wroclaw Medical University
- Target Recruit Count
- 47
- Registration Number
- NCT03398356
- Locations
- 🇵🇱
NZOZ Nowy Dwór, Wroclaw, Lower Silesia, Poland
Research of Intensive Metabolic Intervention Before Pregnancy in PCOS
- Conditions
- PCOSImpaired Glucose Tolerance
- Interventions
- First Posted Date
- 2017-12-26
- Last Posted Date
- 2017-12-26
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 160
- Registration Number
- NCT03383068
- Locations
- 🇨🇳
Renji Hospital Department of Endocrinology and Metabolism, Shanghai, Shanghai, China
Metformin, Vitamin D, and Depression in Polycystic Ovary Syndrome (PCOS) Trial
- Conditions
- Vitamin D DeficiencyPCOSDepressionInsulin Resistance
- Interventions
- First Posted Date
- 2017-12-20
- Last Posted Date
- 2021-02-09
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 5
- Registration Number
- NCT03380091
- Locations
- 🇺🇸
UCSF Center for Reproductive Health, San Francisco, California, United States
Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer
- First Posted Date
- 2017-12-20
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Target Recruit Count
- 49
- Registration Number
- NCT03379909
- Locations
- 🇳🇱
Academic Medical Center, Amsterdam, Netherlands
🇳🇱Sint Franciscus Gasthuis, Rotterdam, Zuid-Holland, Netherlands
🇳🇱RadboudUMC, Nijmegen, Gelderland, Netherlands
Dapagliflozin, Cardio-Metabolic Risk Factors and Type-2 Diabetes
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2018-02-26
- Lead Sponsor
- University of Palermo
- Target Recruit Count
- 186
- Registration Number
- NCT03377335
- Locations
- 🇮🇹
University Hospital of Palermo, Palermo, Italy
IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Haukeland University Hospital
- Target Recruit Count
- 26
- Registration Number
- NCT03378297
- Locations
- 🇳🇴
Helse Bergen HF, Haukeland University Hospital, Bergen, Norway
🇳🇴Helse Stavanger HF, Stavanger University Hospital, Stavanger, Norway
Therapeutic Effects of Compound Zhenzhu Tiaozhi Capsules in NAFLD
- Conditions
- Nonalcoholic Fatty Liver Disease
- Interventions
- First Posted Date
- 2017-12-18
- Last Posted Date
- 2017-12-19
- Lead Sponsor
- The First Affiliated Hospital of Guangdong Pharmaceutical University
- Target Recruit Count
- 196
- Registration Number
- NCT03375580
- Locations
- 🇨🇳
First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.